Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Extremes of Outcome Strategy Provides Evidence for Multiple Sclerosis Severity Being Determined by Alleles at the [italic]HLA-DRB1[/italic] Locus
MS and Related Diseases
(-)
008
Authors/Disclosures
Gabriele C. De Luca, MD, DPhil, FRCPath, FÂé¶¹´«Ã½Ó³»­ (University of Oxford) Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurology Academy. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wellcome Trust. The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from UK MS Society. The institution of Dr. De Luca has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. De Luca has received research support from US Department of Defense. The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from Rosetrees Trust. The institution of Dr. De Luca has received research support from Strategic Innovation Fund, Oxford University. The institution of Dr. De Luca has received research support from Agence National de la Recherche. Dr. De Luca has a non-compensated relationship as a Editorial board member with MS Journal that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. De Luca has a non-compensated relationship as a Steering Group member with MS Academy that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. De Luca has a non-compensated relationship as a Board of Directors with SEQUINS that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. De Luca has a non-compensated relationship as a Editorial board member with Continuum (Âé¶¹´«Ã½Ó³»­) that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. De Luca has a non-compensated relationship as a Editorial board member with Frontiers in Neurology that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Sreeram Ramagopalan No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Matthew R. Lincoln, MD, DPhil FRCPC (St. Michael's Hospital) No disclosure on file
No disclosure on file
Maura Pugliatti, MD No disclosure on file
Neil Risch, MD (Dept of Genetics-MC5120) No disclosure on file
Dessa Sadovnick, PhD (VCHA-UBC Hospital) No disclosure on file
No disclosure on file
Stefano Sotgiu Stefano Sotgiu has nothing to disclose.
No disclosure on file
George C. Ebers, MD No disclosure on file